COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, Jose Antonio Garcia-Marco, José Ángel Hernández-Rivas, Fatima Mirás, Mónica Baile, Juan Marquet, Carsten U. Niemann, Gianluigi Reda, Talha Munir, Eva Gimeno, Monia Marchetti, Francesca Maria Quaglia, Marzia Varettoni, Julio Delgado, Sunil IyengarAnn Janssens, Roberto Marasca, Angela Ferrari, Carolina Cuéllar-García, Gilad Itchaki, Martin Špaček, Lorenzo De Paoli, Luca Laurenti, Mark David Levin, Enrico Lista, Francesca R. Mauro, Martin Šimkovič, Ellen Van Der Spek, Elisabeth Vandenberghe, Livio Trentin, Ewa Wasik-Szczepanek, Rosa Ruchlemer, Dominique Bron, Maria Rosaria De Paolis, Giovanni Del Poeta, Lucia Farina, Myriam Foglietta, Massimo Gentile, Yair Herishanu, Tobias Herold, Ozren Jaksic, Arnon P. Kater, Davide Rossi, Giuseppe Rossi, Paolo Ghia

Research output: Contribution to journalArticle

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus'. Together they form a unique fingerprint.

  • Cite this

    Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernández-Rivas, J. Á., Mirás, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., ... Ghia, P. (Accepted/In press). COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. https://doi.org/10.1038/s41375-020-0959-x